99mTc‐MIP‐1404‐SPECT/CT for the detection of PSMA‐positive lesions in 225 patients with biochemical recurrence of prostate cancer

99mTc‐MIP‐1404 (Progenics Pharmaceuticals, Inc., New York, NY) is a novel, SPECT‐compatible 99mTc‐labeled PSMA inhibitor for the detection of prostate cancer. We present results of its clinical use in a cohort of 225 men with histologically confirmed prostate cancer referred for workup of biochemical relapse.

[1]  T. Eade,et al.  The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study , 2018, The Journal of Nuclear Medicine.

[2]  A. Maes,et al.  Diagnostic sensitivity of Tc‐99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga‐68 PSMA PET/CT , 2017, The Prostate.

[3]  A. Drzezga,et al.  PSA-Stratified Performance of 18F- and 68Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer , 2017, The Journal of Nuclear Medicine.

[4]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. , 2017, European urology.

[5]  John Babich,et al.  Phase 2 Study of 99mTc-Trofolastat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection , 2017, The Journal of Nuclear Medicine.

[6]  Bernd J. Krause,et al.  68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0 , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  Damien Bolton,et al.  Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. , 2016, European urology.

[8]  N. Lawrentschuk,et al.  Updates of prostate cancer staging: Prostate-specific membrane antigen , 2016, Investigative and clinical urology.

[9]  U. Haberkorn,et al.  The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[10]  C. Stief,et al.  68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. , 2016, European urology.

[11]  A. Buck,et al.  68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT , 2016, Clinical nuclear medicine.

[12]  M. Schwaiger,et al.  Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  M. Schwaiger,et al.  Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. , 2016, The Journal of urology.

[14]  Markus Schwaiger,et al.  Current use of PSMA–PET in prostate cancer management , 2016, Nature Reviews Urology.

[15]  R. Knuechel,et al.  Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with 68Ga-PSMA-HBED-CC than with 18F-Fluoroethylcholine PET/CT , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  S. Houshmand,et al.  Role of Optimal Quantification of FDG PET Imaging in the Clinical Practice of Radiology. , 2016, Radiographics : a review publication of the Radiological Society of North America, Inc.

[17]  D. Rubello,et al.  18F-FDG PET/CT quantification in head and neck squamous cell cancer: principles, technical issues and clinical applications , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  C. Nanni,et al.  18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT , 2015, Clinical nuclear medicine.

[19]  Michael Lassmann,et al.  68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies , 2015, The Journal of Nuclear Medicine.

[20]  S. Fanti,et al.  Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy , 2015, The Journal of Nuclear Medicine.

[21]  A. García-Vicente,et al.  Clinical utility of 18F‐fluorocholine positron‐emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study , 2015, BJU international.

[22]  W. Horninger,et al.  68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  T. Kuwert,et al.  Longitudinal analysis of bone metabolism using SPECT/CT and 99mTc-diphosphono-propanedicarboxylic acid: comparison of visual and quantitative analysis , 2015, EJNMMI Research.

[24]  M. Schwaiger,et al.  Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy , 2015, The Journal of Nuclear Medicine.

[25]  T. Holland-Letz,et al.  The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  S. Vallabhajosula,et al.  99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer , 2014, The Journal of Nuclear Medicine.

[27]  F. Fazio,et al.  11C-Choline PET/CT Predicts Prostate Cancer–Specific Survival in Patients with Biochemical Failure During Androgen-Deprivation Therapy , 2014, The Journal of Nuclear Medicine.

[28]  Dong Soo Lee,et al.  Recent Trends in PET Image Interpretations Using Volumetric and Texture-based Quantification Methods in Nuclear Oncology , 2014, Nuclear Medicine and Molecular Imaging.

[29]  M. Loda,et al.  Prostate-Specific Membrane Antigen Protein Expression in Tumor Tissue and Risk of Lethal Prostate Cancer , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[30]  T. Holland-Letz,et al.  Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[31]  W. Eckelman,et al.  99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer , 2013, The Journal of Nuclear Medicine.

[32]  L. Bachmann,et al.  The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. , 2013, European urology.

[33]  S. Vallabhajosula,et al.  2200 A PHASE 1 PILOT STUDY OF 99MTC-MIP-1404 SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT)/CT IMAGING IN MEN WITH PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY , 2013 .

[34]  T. Holland-Letz,et al.  PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[35]  W. Eckelman,et al.  Synthesis and SAR of ⁹⁹mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates. , 2013, Bioorganic & medicinal chemistry letters.

[36]  D. Hörsch,et al.  The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[37]  Joachim Hornegger,et al.  Absolute quantification in SPECT , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[38]  Joachim Hornegger,et al.  Quantitative Accuracy of Clinical 99mTc SPECT/CT Using Ordered-Subset Expectation Maximization with 3-Dimensional Resolution Recovery, Attenuation, and Scatter Correction , 2010, Journal of Nuclear Medicine.

[39]  P. Waldenberger,et al.  18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. , 2010, Radiology.

[40]  V. Bettinardi,et al.  Predictive factors of [11C]choline PET/CT in patients with biochemical failure after radical prostatectomy , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[41]  C. Ganter,et al.  Preliminary Results for Characterization of Pelvic Lymph Nodes in Patients With Prostate Cancer by Diffusion-Weighted MR-Imaging , 2010, Investigative radiology.

[42]  E. Adang,et al.  The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. , 2008, Clinical radiology.

[43]  P. Nelson,et al.  Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. , 2007, Cancer research.

[44]  V. Canzonieri,et al.  [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[45]  J. Quian,et al.  Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. , 2004, Histology and histopathology.

[46]  Prabhjot Kaur,et al.  Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  S. A. Wolfe,et al.  Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer. , 2002, Gene.

[48]  P. Schellhammer,et al.  Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. , 1996, Urology.

[49]  M. Uder,et al.  First Experience With SPECT/CT Using a 99mTc-Labeled Inhibitor for Prostate-Specific Membrane Antigen in Patients With Biochemical Recurrence of Prostate Cancer , 2017, Clinical nuclear medicine.

[50]  U. Haberkorn,et al.  Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[51]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. , 2014, European urology.